Dirk W.
- Country
- Germany
- Department
- Klinik für Gastroenterologie und Hepatologie
Research Overview
- Phase 1/2 Study of Pumitamig Monotherapy or in Combination with Ipilimumab for First-Line Advanced or Unresectable Hepatocellular Carcinoma
- A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX versus mFOLFIRINOX Alone in Patients with Resected Pancreatic Ductal Adenocarcinoma
- Phase 3 Randomized, Double-Blind Study of Pembrolizumab with Gemcitabine/Cisplatin vs. Placebo with Gemcitabine/Cisplatin in Advanced Biliary Tract Carcinoma
Data & Insights
Has run more than one trial at 61 of 152 partner sites.
Specializations
Pancreatic Cancer Research
Focused on innovative treatments for oligometastatic pancreatic cancer and pancreatic ductal adenocarcinoma, investigating both surgical and chemotherapeutic approaches.
- Multimodal surgical interventions
- Neoadjuvant chemotherapy protocols
- Genetic marker-based treatment allocation
Specializes in personalized treatment strategies for resectable and metastatic pancreatic cancer cases.
Liver Cancer Therapeutics
Conducts advanced research in hepatocellular carcinoma (HCC) treatment, exploring immunotherapy combinations and innovative therapeutic approaches.
- Immunotherapy combinations
- Targeted molecular therapies
- Microbiota-based interventions
Explores novel treatment modalities including selective transarterial chemoembolization and immunotherapy resistance.
Biliary Tract Oncology
Investigates treatments for biliary tract cancer, including cholangiocarcinoma and gallbladder cancer.
- Post-surgical therapeutic strategies
- Combined chemotherapy approaches
- Curative resection outcomes
Focuses on developing post-surgical treatment protocols to prevent cancer recurrence.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.